Private equity specialists Bain Capital and Cinven inked a deal to purchase the Specialty Ingredients unit (LSI) of Switzerland-based pharmaceuticals group Lonza for an enterprise value of CHF4 . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.